Literature DB >> 25434832

The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents.

Chengcheng Christine Zhang1, Georg Gdynia1, Volker Ehemann2, Wilfried Roth2.   

Abstract

The HMGB1 protein has multiple functions in tumor biology and can act both as a transcription factor and as a cytokine. HMGB1 is released during cell death, and in our previous studies we demonstrated that HMGB1 induces a distinct, necrosis-like cell death in glioblastoma. In epithelial malignant tumors such as colorectal cancer (CRC), the HMGB1-dependent effects show cross-talk with apoptotic signal transduction. Treatment of CRC cells with low concentrations of recombinant HMGB1 results in dose-dependent cytotoxicity which is morphologically characterized by the formation of giant mitochondria and does not share features of apoptosis. HMGB1-triggered cell death is associated with intracellular ROS release, and overexpression of Bcl-2 blocks both the increase of ROS as well as HMGB1-dependent cell death. Importantly, treatment with recombinant HMGB1 or overexpression of endogenous HMGB1 strongly sensitizes CRC cells to the cytotoxic activity of the pro-apoptotic death ligand TRAIL as well as the small molecule Bcl-2 family inhibitor ABT‑737. Moreover, treatment of CRC cells with TRAIL or ABT‑737 induces a release of endogenous HMGB1 into the extracellular space, and preincubation with glycyrrhizin, an HMGB1 inhibitor, significantly inhibits induction of cell death by TRAIL and ABT‑737, suggesting that HMGB1 functionally contributes to the execution of cell death triggered by pro-apoptotic agents. Finally, we investigated the expression of HMGB1 in human CRC tumor samples and found that loss of HMGB1 expression is associated with a more aggressive phenotype and a more advanced stage of disease in patients with CRC. Altogether, our findings demonstrate a functional link between cytotoxic signaling cascades triggered by HMGB1 and pro-apoptotic agents leading to an HMGB1-dependent sensitization to CRC cell death. Thus, a further evaluation of recombinant HMGB1 as part of an experimental combination treatment of CRC seems warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25434832     DOI: 10.3892/ijo.2014.2785

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  miR-300 mitigates cancer-induced bone pain through targeting HMGB1 in rat models.

Authors:  Chenglong Liu; Jianping Yang; Haihua Liu; Tian Xia; Fei Zhang
Journal:  Genes Genomics       Date:  2019-12-23       Impact factor: 1.839

Review 2.  HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.

Authors:  Kim Jun Cheng; Mohammed Abdullah Alshawsh; Elsa Haniffah Mejia Mohamed; Surendran Thavagnanam; Ajantha Sinniah; Zaridatul Aini Ibrahim
Journal:  Cell Oncol (Dordr)       Date:  2019-11-01       Impact factor: 6.730

3.  miR-142-3p reduces the viability of human cervical cancer cells by negatively regulating the cytoplasmic localization of HMGB1.

Authors:  Hui Dong; Jie Song
Journal:  Exp Ther Med       Date:  2021-01-14       Impact factor: 2.447

4.  Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia.

Authors:  Sara Shayan; Arash Arashkia; Golnaz Bahramali; Asghar Abdoli; Mohammad Sadegh Shams Nosrati; Kayhan Azadmanesh
Journal:  Cancer Cell Int       Date:  2022-04-27       Impact factor: 6.429

5.  Diclofenac-Induced Cytotoxicity in Direct and Indirect Co-Culture of HepG2 Cells with Differentiated THP-1 Cells.

Authors:  Atsushi Kawase; Ouka Takashima; Satsuki Tanaka; Hiroaki Shimada; Masahiro Iwaki
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

6.  Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer.

Authors:  Jialing Zhang; Bin Yan; Stephan Stanislaw Späth; Hu Qun; Shaleeka Cornelius; Daogang Guan; Jiaofang Shao; Koichi Hagiwara; Carter Van Waes; Zhong Chen; Xiulan Su; Yongyi Bi
Journal:  Cell Biosci       Date:  2015-09-17       Impact factor: 7.133

7.  Association of HMGB1 Gene Polymorphisms with Risk of Colorectal Cancer in a Chinese Population.

Authors:  Jian-Xin Wang; Hua-Long Yu; Shao-Sheng Bei; Zhen-Hua Cui; Zhi-Wen Li; Zhen-Ji Liu; Yan-Feng Lv
Journal:  Med Sci Monit       Date:  2016-09-26

8.  High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.

Authors:  Leslee Sprague; Joel M Lee; Brian J Hutzen; Pin-Yi Wang; Chun-Yu Chen; Joe Conner; Lynne Braidwood; Kevin A Cassady; Timothy P Cripe
Journal:  Viruses       Date:  2018-03-15       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.